Prostate Cancer Treatment Market Size, Share, and Trends 2025 to 2034

Prostate Cancer Treatment Market Size and Growth

The global prostate cancer treatment market size is calculated at USD 14.75 billion in 2024, grow to USD 16.05 billion in 2025, and is projected to reach around USD 34.28 billion by 2034, growing at a CAGR of 8.8% from 2025 to 2034. The market is growing due to the rising incidence of prostate cancer globally and increased awareness, leading to early diagnosis. Advancements in targeted therapies and minimally invasive treatment options are also boosting market demand.

Key Takeaways

• North America dominated the prostate cancer treatment market revenue shares in 2024.
• Asia-Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
• By drug class, the hormonal therapy segment dominated the market with a revenue share.
• By drug class, the immunotherapy segment is expected to grow at the fastest CAGR in the market during the studied years.
• By distribution channel, the hospital pharmacies segment held the largest market share.
• By distribution channel, the online pharmacies segment is expected to grow at the fastest CAGR in the market during the studied years.

How is Innovation Impacting the Prostate Cancer Treatment Market?

Prostate cancer treatment is the clinical management of cancer that development in the prostate gland, involving in the prostate gland, involving a range of therapeutic approaches such as surgery, radiation therapy, chemotherapy, hormonal therapy immunotherapy, and targeted drug treatment, tailored to the stage and aggressiveness of the disease as well as the patients’s overall health. Innovation is transforming the prostate cancer treatment market by introducing advanced therapies like PSMA-targeted radioligand therapy, next-generation hormone blockers, and minimally invasive surgical techniques. These breakthroughs allow for more precise targeting of cancer cells, fewer side effects, and improved patient outcomes. Additionally, the integration of AI in diagnostics and personalized treatment planning is enhancing early detection and therapy selection, driving better results and expanding treatment options for patients at various stages of the disease.

What are the Key Trends in the Prostate Cancer Treatment Market in 2025?

In March 2025, AbbVie announced it will present new early-stage oncology data at the AACR Annual Meeting from April 25–30, 2025. Highlights include investigational therapies ABBV-969 and ABBV-514, targeting difficult-to-treat tumors. The research also explores treatment resistance and novel biomarkers using real-world data. ABBV-969, a dual-targeted antibody-drug conjugate with a proprietary Top1 inhibitor payload, is being studied in Phase 1 trials for metastatic castration-resistant prostate cancer, targeting STEAP1 and PSMA antigens commonly linked to tumor progression.

In October 2024, Sanofi joined forces with Orano Med, a specialist in targeted alpha therapies, to accelerate the development of advanced radioligand treatments. This collaboration aims to combine their strengths to enhance the fight against rare cancers and bring next-generation therapies to patients more efficiently.

How Can AI Affect the Prostate Cancer Treatment Market?

AI is significantly transforming the market by enabling earlier and more accurate diagnoses through advanced imaging analysis and predictive algorithms. It aids in personalizing treatment plans by analyzing vast datasets, including genetic profiles, to match patients with the most effective therapies. AI also streamlines drug discovery and clinical trial design, accelerating innovation. Overall, AI enhances decision-making, reduces human error, and improves treatment outcomes, making cancer care more efficient and patient-centered.

Report Scope of Prostate Cancer Treatment Market

Market Dynamics

Driver

Rising Prevalence of Prostate Cancer

The growing number of prostate cancer cases globally is fueling the need for improved treatment solutions. With the disease becoming more common, especially among older adults, healthcare providers are under pressure to adopt innovative therapies and technologies. This urge in cases also prompts governments and organizations to increase funding and research efforts, accelerating the development and availability of advanced treatments, thereby acting as a strong driving force in the prostate cancer treatment market.

For Instance, In November 2024, Europa Uomo representatives in Hungary and Italy promoted prostate cancer awareness through screening initiatives as part of the "Movember" campaign, encouraging early detection and public engagement.

Restraint

High Cost of Advanced Therapeutic

The expensive nature of advanced prostate cancer treatment poses a major challenge, as it restricts widespread adoption across healthcare systems with limited resources. Many patients, especially in developing regions, struggle to afford cutting-edge therapies like precision medicines and high-tech surgical procedures. This financial burden can lead to unequal access, delayed interventions, and lower treatment uptake, thereby hindering the overall progress and expansion of the prostate cancer treatment market.

Opportunity

Government Initiatives Supporting New Treatments

Supportive government action is creating strong prospects for the prostate cancer treatment market by fostering innovation and streamlining regulatory pathways. Through strategic investments, research grants, and national screening initiatives, the government is helping to bring advanced therapies to market faster. These policies not only promote early detection and treatment but also enhance affordability and accessibility, particularly in the public healthcare system, paving the way for broader adoption of cutting-edge treatment and improved patient care outcomes.

For Instance, In November 2023, the Australian Government allocated $5 million to Monash University to explore CAR T-cell therapy for prostate cancer—an advanced immunotherapy previously applied to blood cancers, now being tested for solid tumors. Likewise, the U.S. Department of Defense is supporting various research projects aimed at early detection and precision-targeted treatment approaches, highlighting global efforts to advance innovative solutions in prostate cancer care.

Segmental Insights

How will the Hormonal Therapy Segment Dominate the Prostate Cancer Treatment Market in 2024?

Hormonal therapy holds the largest share in the market because it plays a critical role in slowing disease progression, especially, especially in patients with late-stage or recurring cancer. Its ability to suppress testosterone, which prostate cancer cells depend on, makes it a go-to option for long-term disease control. Additionally, the development of next-generation hormone therapies with improved efficacy has reinforced their widespread clinical use and strong market position over the years.

The immunotherapy segment is anticipated to grow rapidly in the prostate cancer treatment market as it offers a novel approach for tackling tumors that are unresponsive to traditional therapies. With continuous breakthroughs in immune-based treatments like personalized vaccines and T-cell engineering, this segment is gaining momentum. Increased clinical focus, promising patient outcomes, and greater immuno-oncology are fueling its expansion, making it a promising area for future treatment strategies and market growth.

Why Did the Hospital Pharmacies Segment Dominate the Market in 2024?

The dominance of the hospital pharmacy segment in the prostate cancer treatment market is driven by the centralized distribution of complex therapies and the need for continuous medical oversight. Hospitals often manage advanced cases that require specialized treatments like infusion or targeted therapies, which are typically administered in clinical settings. Additionally, hospitals ensure timely access to medication, manage side effects effectively, and offer integrated care, making them the preferred source for prostate cancer treatment distribution.

The online pharmacy segment is expected to grow rapidly in the prostate cancer treatment market due to increasing patient preference for hassle-free, home-based medication access. As digital platforms become more secure and user-friendly, patients are turning to online services for refilling prescriptions, especially those undergoing long-term treatment. The rise in e-health literacy, wider digital reach, and ease of comparing prices and availability online contribute to it-paced growth, particularly in areas lacking nearby healthcare facilities.

Regional Insights

How is North America Contributing to the Expansion of the Prostate Cancer Treatment Market?

North America leads the market due to its advanced healthcare infrastructure, high prevalence of the disease, and early adoption of innovative therapies. The region benefits from significant investments in research and development, leading to early access to novel treatments such as targeted therapies and immunotherapies.  Additionally, widespread awareness campaigns and robust screening programs contribute to early diagnosis and increased treatment uptake.  The presence of key market players and favorable reimbursement policies further boosts the dominance of North America in the global prostate cancer treatment market.

For Instance, In March 2025, the U.S. FDA broadened the use of 177Lu-PSMA-617, allowing it to be administered earlier in the treatment process. Initially, it was approved only for patients with metastatic castration-resistant prostate cancer who had already undergone treatment with an androgen receptor pathway inhibitor and taxane-based chemotherapy. The expanded approval now offers more patients access to this targeted therapy at an earlier stage of their treatment journey.

How is Asia-Pacific approaching the Prostate Cancer Treatment Market in 2024?

The Asia-Pacific region is projected to experience the fastest CAGR in the market due to the rising incidence of prostate cancer, particularly in countries like China and Japan, driven by aging populations and lifestyle changes.  Additionally, increasing healthcare investments and improvements in medical infrastructure are enhancing access to advanced diagnostic and therapeutic options.  Government-led health campaigns and the adoption of innovative treatments, such as targeted therapies and radiopharmaceuticals, are further propelling market growth in the region.  

• For Instance, In February 2023, Japan’s Ministry of Health, Labour, and Welfare approved the use of darolutamide (Nubeqa) alongside androgen deprivation therapy and docetaxel for treating metastatic prostate cancer. This approval highlights progress in expanding treatment choices for patients in Japan, offering a more effective therapeutic approach for advanced stages of the disease.

Top Companies in the Prostate Cancer Treatment Market

• Johnson & Johnson Services, Inc.
• Astellas Pharma Inc.
• Eli Lilly and Company
• Sanofi
• Ipsen Pharma
• Bayer AG
• AstraZeneca
• Bausch Health Companies Inc.
• Merck & Co., Inc.
• Pfizer Inc.

Recent Developments in the Prostate Cancer Treatment Market

• In September 2024, Tolmar, Inc. partnered with Pharma and GmbH to support the promotion of Rubraca (rucaparib) in the U.S. for treating metastatic castration-resistant prostate cancer (mCRPC). While Tolmar focused on the prostate cancer indication in the U.S., Pharma& continued its efforts to promote Rubraca for approved uses in advanced ovarian cancer across both the U.S. and European markets.
• In April 2024, Astellas Pharma Inc. gained approval from the European Commission to expand the use of XTANDI (enzalutamide). The approval allows the drug to be used alone or alongside androgen deprivation therapy for adult men with high-risk, non-metastatic, hormone-sensitive prostate cancer who experience biochemical recurrence and are not candidates for salvage radiotherapy.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Prostate Cancer Treatment Market.

By Drug Class 

• Hormonal Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Others

By Distribution Channel 

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Regional

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)